CN102166329A - Medicine for treating leukopenia caused by chronic hepatitis B or interferon and preparation method thereof - Google Patents
Medicine for treating leukopenia caused by chronic hepatitis B or interferon and preparation method thereof Download PDFInfo
- Publication number
- CN102166329A CN102166329A CN 201010128834 CN201010128834A CN102166329A CN 102166329 A CN102166329 A CN 102166329A CN 201010128834 CN201010128834 CN 201010128834 CN 201010128834 A CN201010128834 A CN 201010128834A CN 102166329 A CN102166329 A CN 102166329A
- Authority
- CN
- China
- Prior art keywords
- grams
- preparation
- medicine
- chronic hepatitis
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 208000000419 Chronic Hepatitis B Diseases 0.000 title claims abstract description 21
- 208000002672 hepatitis B Diseases 0.000 title claims abstract description 21
- 102000014150 Interferons Human genes 0.000 title claims abstract description 15
- 108010050904 Interferons Proteins 0.000 title claims abstract description 15
- 229940079322 interferon Drugs 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 201000002364 leukopenia Diseases 0.000 title abstract description 15
- 231100001022 leukopenia Toxicity 0.000 title abstract description 15
- 229940079593 drug Drugs 0.000 title description 10
- 238000007670 refining Methods 0.000 claims abstract description 8
- 239000006187 pill Substances 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims description 17
- 239000008187 granular material Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 241000756943 Codonopsis Species 0.000 claims description 6
- 239000009636 Huang Qi Substances 0.000 claims description 6
- 230000000610 leukopenic effect Effects 0.000 claims description 6
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 6
- 235000012907 honey Nutrition 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 240000005629 Curcuma phaeocaulis Species 0.000 abstract 1
- 235000003391 Curcuma phaeocaulis Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 241000329195 Sparganium erectum Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 238000004140 cleaning Methods 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- XDBMTQVSHNQIFU-UHFFFAOYSA-N 2-(2-ethoxy-2-oxo-1-phenylethyl)-1,3-thiazolidin-3-ium-4-carboxylate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)C1NC(C(O)=O)CS1 XDBMTQVSHNQIFU-UHFFFAOYSA-N 0.000 description 11
- 241000608867 Leucogenes Species 0.000 description 11
- 230000000388 leucogen effect Effects 0.000 description 11
- 210000000265 leukocyte Anatomy 0.000 description 11
- 238000011084 recovery Methods 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 7
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- 206010039897 Sedation Diseases 0.000 description 4
- 230000036280 sedation Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 229960003513 batilol Drugs 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- IQSFEAHJUMVILC-UHFFFAOYSA-N Isorhynchophyllic acid Natural products CCC1CN2CCC3(C2CC1C(=COC)C(=O)O)C(=O)Nc4ccccc34 IQSFEAHJUMVILC-UHFFFAOYSA-N 0.000 description 1
- DAXYUDFNWXHGBE-VKCGGMIFSA-N Isorhynchophylline Chemical compound O=C1NC2=CC=CC=C2[C@]11CCN2C[C@H](CC)[C@@H](\C(=C/OC)C(=O)OC)C[C@H]21 DAXYUDFNWXHGBE-VKCGGMIFSA-N 0.000 description 1
- VCNYNWHVJKWJRQ-UHFFFAOYSA-N Isorhynchophylline Natural products CCC1=CN2CCC3(C2CC1C(=COC)C(=O)OC)C(=O)Nc4ccccc34 VCNYNWHVJKWJRQ-UHFFFAOYSA-N 0.000 description 1
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 206010023683 lagophthalmos Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 description 1
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Natural products C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine for treating leukopenia caused by chronic hepatitis B or interferon and preparation method thereof. The medicine is characterized by being prepared from the following important ingredients: 20 to 30 grams of astragalus root, 6 to 10 grams of Chinese angelica, 8 to 12 grams of common burreed rhizome, 8 to 12 grams of curcuma phaeocaulis valeton, 8 to 12 grams of prepared rehmannia root, 8 to 12 grams of white paeony root, 8 to 12 grams of hairy asiabell root, and 3 to 5 grams of fried liquorice. The preparation method of the medicine comprises following steps of cleaning the above ingredients, sieving, refining honey, and then, producing medicinal pills. The medicine has advantages of simpleness in preparation, convenience in taking, excellent and durable curative effect, no toxic or side effects, and low cost, and is especially suitable for treating patients with leukopenia caused by chronic hepatitis B or interferon.
Description
Technical field:
The present invention relates to a kind of Chinese herbal medicine, leukopenic medicine due to particularly a kind of treatment chronic hepatitis B or the interferon and preparation method thereof.
Background technology:
Chronic hepatitis B is one of common chronic infectious disease of China, and serious harm people ' s health, leukopenia are the common situations in the therapeutic process that reaches in its pathogenic process.Leukopenia is meant that the peripheral blood leucocyte counting continues to be lower than normal value 4 * 10
9/ L, its paathogenic factor is a lot, as ionizing radiation, chemical toxicant (as benzene etc.), Cytotoxic drugs, malnutrition, malignant tumor, leukemia, viral hepatitis etc.Wherein, majority is optimum process, but person due to (the most common is adverse Reaction of Interferon) in chronic hepatitis B and the therapeutic process thereof, single still effective when just sending out with leucogen, batilol, DIYU SHENGBAI PIAN etc., do not send out again the many unsatisfactory curative effects of person, and the said medicine composition is single, price is higher, curative effect is difficult for lastingly.
Summary of the invention:
Purpose of the present invention be exactly to provide a kind of make simple, taking convenience, evident in efficacy and lasting, have no side effect, cheap treatment chronic hepatitis B or the leukopenic medicine due to the interferon and preparation method thereof.
The object of the present invention is achieved like this: leukopenic medicine due to a kind of treatment chronic hepatitis B or the interferon and preparation method thereof is characterized in that it mainly is grouped into by following one-tenth: Radix Astragali 20-30g, Radix Angelicae Sinensis 6-10g, rhizoma sparganic 8-12g, Rhizoma Curcumae 8-12g, Radix Rehmanniae Preparata 8-12g, Radix Paeoniae Alba 8-12g, Radix Codonopsis 8-12g, Radix Glycyrrhizae Preparata 3-5g.
Preparation method of the present invention may further comprise the steps:
1) cleans: raw material is mixed, clean up with clear water;
2) sieve: cleaned raw material is put into drying baker dry, grind into powder then, reuse 100 purpose sieves sieve raw material, and the medicamental pulverata that granule is little filters out, and for future use, grinding into powder again that granule is big sieved;
3) refining Mel: Mel is put into pot with the low baking temperature refining, coagulate as the maltosemalt sugar shape, the not order of stirring is burnt, and the addition of Mel is 1 times of raw-material weight;
4) make pill: the Mel of refining is mixed with above-mentioned medicamental pulverata rubs by evenly, placement pact half an hour, rub once more by, the honeyed pill of making about 6g gets final product.
The present invention also can be made into medicamental pulverata electuary, capsule.
The major function of each component of the present invention:
The Radix Astragali: tonifying Qi and lifting yang, benefiting QI for strengthening the superficies, inducing diuresis to remove edema, holder skin ulcer granulation promoting are monarch drug, contain glycoside, polysaccharide, aminoacid and trace element etc., have Ramulus Uncariae cum Uncis alkali, isorhynchophylline etc., the Ramulus Uncariae Cum Uncis decoct is injected to mouse peritoneal, can produce tangible sedation, its ethanol extract can be prevented the outbreak of Cavia porcellus epilepsy reaction, and the irritability of maincenter motor analyzer is increased certain inhibitory action.
Radix Angelicae Sinensis: suppressing the hyperactive liver and subsiding YANG, liver heat removing and eyesight improving, with Ramulus Uncariae Cum Uncis be monarch drug altogether, contain the iodine of calcium carbonate, organic matter and magnesium, ferrum, silicate, phosphate, chloride and denier, sedation is arranged, too much gastric acid under one's belt can neutralize.
Radix Codonopsis: resuscitation inducing and mind tranquilizing, removing dampness to restore normal function of the stomach are ministerial drug, contain volatile oil, aminoacid, organic acid and saccharide, and its water decoction, volatile oil have sedation, and water decoction has anticonvulsant action.
Radix Rehmanniae Preparata: drying dampness to eliminate phlegm, stopping nausea and vomiting by lowering the adverse flow of QI are ministerial drug, contain glycoside, several amino acids, volatile oil, Saponin, choline etc., coughing centre there is sedation, can remove bronchospasm, and bronchus secretion is reduced and Antitussive and Expectorant Effect is arranged, can suppress vomiting center and preventing or arresting vomiting, it is intrinsic pressure that decoct can reduce lagophthalmos, and the stopping nausea and vomiting by lowering the adverse flow of QI effect is better behind the processed with Rhizoma Zingiberis Recens.
The Radix Paeoniae Alba: dispelling wind and heat pathogens, suppressing the hyperactive liver make eye bright, heat-clearing and toxic substances removing is ministerial drug, contain volatile oil, chrysanthemum glycoside, adenine, choline, stachydrine, aminoacid etc., its preparation has coronary artery dilator, coronary blood flow increasing, improve the effect of myocardial oxygen consumption, and have hypotensive effect.
Rhizoma sparganic: dispelling wind and heat pathogens, rash are antipruritic, improving acuity of vision and removing nebula, relieving convulsion are ministerial drug, contain a large amount of chitins, protein, aminoacid, organic acid etc., have anticonvulsant action.
Rhizoma Curcumae: promoting diuresis to eliminate damp pathogen, spleen-benefiting mind-tranquilizing are ministerial drug, contain pachyman, pachymic acid, protein, fat, lecithin, choline etc., tool calmness, diuresis, increase myocardial contraction, hypoglycemic activity.
Radix Glycyrrhizae Preparata: regulating qi-flowing for strengthening spleen, drying dampness to eliminate phlegm are ministerial drug, contain volatile oil, flavonoid glycoside, nobiletin and vitamin B
1, C etc., low dose of heart tonifying, increase cardiac output, coronary artery dilator, can the fortifying fibre protein dissolution, antithrombotic forms, and choleretic effect is arranged.
Therapeutic effect was obvious after most of patients was taken this Chinese medicine, illustrated (for the protection patients ' privacy, saving its name):
| Name | Sex | Age | Consultation time | Treatment process | Symptom | The situation of taking medicine |
| The temperature certain | The man | 38 years old | In October, 2003 | Suffer from chronic hepatitis B, with occurring leukopenia February behind the interferon therapy, hospital treatment once, more back recurrence | The peripheral blood leucocyte counting continues to be lower than normal value 4 * 10 9/ L accompanies weak | Once took the leucogen, recovery from illness back recurrence is obeyed behind 21 doses in this Chinese medicine more, follows up a case by regular visits to not recurrence in 2 years |
| Hao | The man | 43 | In JIUYUE, 2000 | Suffer from chronic hepatitis B and caused leukopenia 1 year, once hospital treatment recurred after healing | The peripheral blood leucocyte counting continues to be lower than normal value 4 * 10 9/ L accompanies weak, happiness lazy moving for sleeping in | Once took leucogen, batilol, recovery from illness back recurrence is obeyed behind 60 doses in this Chinese medicine more, follows up a case by regular visits to not recurrence in 2 years |
| Lee | The man | 49 | In June, 2002 | Suffer from chronic hepatitis B and cause leukopenia August, hospital treatment once, more back recurrence | The peripheral blood leucocyte counting continues to be lower than normal value 4 * 10 9/ L does not have uncomfortable | Once took the leucogen, recovery from illness back recurrence is obeyed behind 30 doses in this Chinese medicine more, follows up a case by regular visits to not recurrence in 2 years |
| Grandson | The woman | 36 | In March, 2005 | Suffer from chronic hepatitis B, with occurring leukopenia June behind the interferon therapy, hospital treatment once, more back recurrence | The peripheral blood leucocyte counting continues to be lower than normal value 4 * 10 9/ L accompanies weak | Once took leucogen, DIYU SHENGBAI PIAN, recovery from illness back recurrence is obeyed behind 30 doses in this Chinese medicine more, follows up a case by regular visits to not recurrence in 2 years |
| Chen | The woman | 33 | In November, 2004 | Suffer from chronic hepatitis B, with occurring leukopenia March behind the interferon therapy, hospital treatment once, more back recurrence | The peripheral blood leucocyte counting continues to be lower than normal value 4 * 10 9/ L accompanies weak | Once took leucogen, batilol, recovery from illness back recurrence is obeyed behind 24 doses in this Chinese medicine more, follows up a case by regular visits to not recurrence in 2 years |
| Lu | The woman | 45 | In February, 2005 | Suffer from chronic hepatitis B and caused leukopenia 13 months, once hospital treatment recurred after healing | The peripheral blood leucocyte counting continues to be lower than normal value 4 * 10 9/ L does not have uncomfortable | Once took leucogen, DIYU SHENGBAI PIAN, recovery from illness back recurrence is obeyed behind 45 doses in this Chinese medicine more, follows up a case by regular visits to not recurrence in 2 years |
| The Wang | The man | 41 | In April, 2006 | Suffer from chronic hepatitis B, with occurring leukopenia March behind the interferon therapy, hospital treatment once, more back recurrence | The peripheral blood leucocyte counting continues to be lower than normal value 4 * 10 9/ L accompanies weak | Once took leucogen, DIYU SHENGBAI PIAN, recovery from illness back recurrence is obeyed behind 30 doses in this Chinese medicine more, follows up a case by regular visits to not recurrence in 2 years |
| Zhang | The man | 39 | In March, 2007 | Suffer from chronic hepatitis B and cause leukopenia May, hospital treatment once, more back recurrence | The peripheral blood leucocyte counting continues to be lower than normal value 4 * 10 9/ L accompanies weak | Once took the leucogen, more back recurrence of convulsion is obeyed behind 21 doses in this Chinese medicine more, follows up a case by regular visits to not recurrence in 2 years |
| Teng | The man | 47 | In February, 2007 | Suffer from chronic hepatitis B and cause leukopenia March, hospital treatment once, more back recurrence | The peripheral blood leucocyte counting continues to be lower than normal value 4 * 10 9/ L does not have uncomfortable | Once took the leucogen, recovery from illness back recurrence is obeyed behind 21 doses in this Chinese medicine more, follows up a case by regular visits to not recurrence in 2 years |
| Cao | The man | 33 | In October, 2008 | Suffer from chronic hepatitis B, with occurring leukopenia July behind the interferon therapy, hospital treatment once, more back recurrence | The peripheral blood leucocyte counting continues to be lower than normal value 4 * 10 9/ L, companion's poor appetite, weak, lazy moving | Once took leucogen, DIYU SHENGBAI PIAN, recovery from illness back recurrence is obeyed behind 45 doses in this Chinese medicine more, follows up a case by regular visits to not recurrence in a year |
The specific embodiment:
Embodiment 1: to make pill is example, gets the Radix Astragali 20 grams, Radix Angelicae Sinensis 7 grams, Radix Codonopsis 12 grams, Radix Rehmanniae Preparata 12 grams, the Radix Paeoniae Alba 12 grams, rhizoma sparganic 12 grams, Rhizoma Curcumae 12 grams, Radix Glycyrrhizae Preparata 3 grams; At first above-mentioned raw material is mixed, clean up; Again cleaned raw material is put into drying baker and dry, grind to form graininess then, reuse 100 purpose sieves sieve ground raw material, and the medicine that granule is little filters out, and for future use, grinding into powder again that granule is big sieved; Then 90 gram Mel are put into pot with the low baking temperature refining, coagulate as the maltosemalt sugar shape, the not order of stirring is burnt; At last refined honey is mixed with above-mentioned medicamental pulverata and rubs by evenly, place half an hour approximately, rub once more by, the honeyed pill of making about 6 grams gets final product;
Embodiment 2: to make the medicamental pulverata electuary is example, gets the Radix Astragali 28 grams, Radix Angelicae Sinensis 8 grams, Radix Codonopsis 10 grams, Radix Rehmanniae Preparata 10 grams, the Radix Paeoniae Alba 11 grams, rhizoma sparganic 11 grams, Rhizoma Curcumae 11 grams, Radix Glycyrrhizae Preparata 4 grams; At first above-mentioned raw material is mixed, clean up; Again cleaned raw material is put into drying baker and dry, grind to form graininess then, reuse 100 purpose sieves sieve ground raw material, the medicine that granule is little filters out, for future use, grinding into powder again that granule is big sieved, and is that the unit pack gets final product with 6 grams at last;
Embodiment 3: to make capsule is example, gets the Radix Astragali 30 grams, Radix Angelicae Sinensis 8 grams, Radix Codonopsis 10 grams, Radix Rehmanniae Preparata 10 grams, the Radix Paeoniae Alba 10 grams, rhizoma sparganic 10 grams, Rhizoma Curcumae 10 grams, Radix Glycyrrhizae Preparata 5 grams; At first above-mentioned raw material is mixed, clean up; Again cleaned raw material is put into drying baker and dry, grind to form graininess then, reuse 100 purpose sieves sieve ground raw material, the medicine that granule is little filters out, for future use, grinding into powder again that granule is big sieved, and incapsulates with 0.5 gram at last to get final product.
Claims (2)
1. leukopenic medicine due to a treatment chronic hepatitis B or the interferon and preparation method thereof, it is characterized in that it mainly is grouped into by following one-tenth: Radix Astragali 20-30g, Radix Angelicae Sinensis 6-10g, rhizoma sparganic 8-12g, Rhizoma Curcumae 8-12g, Radix Rehmanniae Preparata 8-12g, Radix Paeoniae Alba 8-12g, Radix Codonopsis 8-12g, Radix Glycyrrhizae Preparata 3-5g
2. leukopenic medicine due to a treatment chronic hepatitis B or the interferon and preparation method thereof is characterized in that preparation method of the present invention may further comprise the steps:
1) cleans: raw material is mixed, clean up with clear water;
2) sieve: cleaned raw material is put into drying baker dry, grind into powder then, reuse 100 purpose sieves sieve raw material, and the medicamental pulverata that granule is little filters out, and for future use, grinding into powder again that granule is big sieved;
3) refining Mel: Mel is put into pot with the low baking temperature refining, coagulate as the maltosemalt sugar shape, the not order of stirring is burnt, and the addition of Mel is 1 times of raw-material weight;
4) make pill: the Mel of refining is mixed with above-mentioned medicamental pulverata rubs by evenly, placement pact half an hour, rub once more by, the honeyed pill of making about 6g gets final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101288342A CN102166329B (en) | 2010-03-17 | 2010-03-17 | Medicine for treating leukopenia caused by chronic hepatitis B or interferon and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101288342A CN102166329B (en) | 2010-03-17 | 2010-03-17 | Medicine for treating leukopenia caused by chronic hepatitis B or interferon and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102166329A true CN102166329A (en) | 2011-08-31 |
| CN102166329B CN102166329B (en) | 2012-08-22 |
Family
ID=44487772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101288342A Expired - Fee Related CN102166329B (en) | 2010-03-17 | 2010-03-17 | Medicine for treating leukopenia caused by chronic hepatitis B or interferon and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102166329B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104906244A (en) * | 2015-07-02 | 2015-09-16 | 赵成茂 | Traditional Chinese medicine composition for treating leucopenia |
| CN111214633A (en) * | 2020-03-09 | 2020-06-02 | 耿禄 | Formula for treating infectious hepatitis B |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101357219A (en) * | 2008-09-04 | 2009-02-04 | 兰州佛慈制药股份有限公司 | Medicine for treating chronic hepatitis b |
| CN101385842A (en) * | 2008-10-14 | 2009-03-18 | 王林兴 | Medicine for treating chronic hepatitis b and preparation method thereof |
-
2010
- 2010-03-17 CN CN2010101288342A patent/CN102166329B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101357219A (en) * | 2008-09-04 | 2009-02-04 | 兰州佛慈制药股份有限公司 | Medicine for treating chronic hepatitis b |
| CN101385842A (en) * | 2008-10-14 | 2009-03-18 | 王林兴 | Medicine for treating chronic hepatitis b and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| > 20040430 钟有添等 中医药治疗病毒性乙型肝炎研究进展 224-227 1-2 第24卷, 第2期 2 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104906244A (en) * | 2015-07-02 | 2015-09-16 | 赵成茂 | Traditional Chinese medicine composition for treating leucopenia |
| CN104906244B (en) * | 2015-07-02 | 2017-11-10 | 赵成茂 | A kind of Chinese medicine composition for treating leukopenia |
| CN111214633A (en) * | 2020-03-09 | 2020-06-02 | 耿禄 | Formula for treating infectious hepatitis B |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102166329B (en) | 2012-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104055935B (en) | It is a kind of to cooperate with the Chinese medicine composition for improving immunity | |
| CN104491695A (en) | Pharmaceutical composition for treating chloasma | |
| CN102166329B (en) | Medicine for treating leukopenia caused by chronic hepatitis B or interferon and preparation method thereof | |
| CN101390970A (en) | A kind of traditional Chinese medicine for treating hepatitis B and its preparation method | |
| CN108635389A (en) | A kind of preparation method of Chinese medicine preparation and its electuary that treating diabetes B | |
| CN102631498B (en) | Chinese medicine composition | |
| CN102319388A (en) | Traditional Chinese medicine granules for treating epigastric pain and preparation method thereof | |
| CN108815448B (en) | Traditional Chinese medicine granules for treating chronic colitis | |
| CN102188675B (en) | Medicine for treating peripheral vertigo, and preparation thereof | |
| CN105477465A (en) | Chinese herb preparation with liver protection function and preparing technology of Chinese herb preparation | |
| CN104971241A (en) | Traditional Chinese medicinal composition for treating cerebral thrombus, and preparation method thereof | |
| CN102631506B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN103919972B (en) | A kind of pharmaceutical composition of resisting fatigue and its preparation method and application | |
| CN102764385A (en) | Medicine for treating venereophobia and application of medicine | |
| CN102631492A (en) | Chinese medicinal composition for improving immunity and resisting fatigue | |
| CN102631486B (en) | Health care composition | |
| CN110251605A (en) | A kind of drug for treating hyperthyroidism or tumour | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN1449782A (en) | Compound cactsu antivirus preparation | |
| CN107362301A (en) | Fragrant Siberian cocklebur appetizing particle | |
| CN105327003A (en) | Traditional Chinese medicine for treating cardiovascular diseases and preparation method thereof | |
| CN104888080A (en) | Traditional Chinese medicine composition for treating insomnia | |
| CN103784876B (en) | A kind of Chinese medicine formula treating herpes zoster and preparation method thereof | |
| CN102631493B (en) | Health care composition | |
| CN105412322A (en) | Traditional Chinese medicine preparation for treating diabetic peripheral neuropathic pain and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120822 Termination date: 20130317 |